Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET APPLICATION COVERAGE GRID
2.8 PRODUCT LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTAL ANALYSIS
4.2 PORTER’S FIVE FORCES
4.3 PESTEL ANALYSIS
5 COST STRUCTURE ANALYSIS OF ANTIBODY-DRUG CONJUGATE (ADC) MANUFACTURING
5.1 ANTIBODIES
5.1.1 OVERVIEW OF ANTIBODY PRODUCTION
5.1.1.1 In-house vs. Outsourced:
5.1.2 ANTIBODY PRICING FACTORS
5.2 LINKERS
5.2.1 ROLE AND TYPES OF LINKERS
5.2.1.1 Cost Impact by Linker Type:
5.3 CYTOTOXIC AGENTS
5.3.1 COST CONSIDERATIONS:
5.3.2 BUFFERS AND SOLVENTS
5.4 COST BREAKDOWN BY MANUFACTURING STAGE
5.4.1 PRE-PRODUCTION COSTS
5.4.2 CONJUGATION PROCESS
5.4.3 PURIFICATION AND FILTRATION
5.4.4 QUALITY CONTROL
5.5 COST PROJECTIONS AND PRICING TRENDS (2024–2030)
5.5.1 PROJECTED COST FLUCTUATIONS
5.5.2 COST IMPACT OF SCALABILITY
5.6 SUPPLIER AND GEOGRAPHIC PRICING TRENDS
5.6.1 GEOGRAPHIC COST VARIATIONS
5.6.2 SUPPLIER ANALYSIS
5.6.3 CONCLUSION
6 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: REGULATIONS
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 INCREASING PREVALENCE OF CANCER
7.1.2 ADVANCES IN ANTIBODY-DRUG CONJUGATE (ADC) TECHNOLOGY
7.1.3 INCREASING DEMAND FOR TARGETED THERAPIES
7.1.4 ADVANCEMENTS IN PROTEOMICS AND GENOMICS RESEARCH
7.2 RESTRAINTS
7.2.1 HIGH DEVELOPMENT COST & MANUFACTURING COMPLEXITIES
7.2.2 SAFETY AND TOXICITY ISSUES OF ANTIBODY DRUG CONJUGATES
7.3 OPPORTUNITIES
7.3.1 GROWING ONCOLOGY PIPELINE FOR ANTIBODY DRUG CONJUGATES (ADCS)
7.3.2 INCREASING INVESTMENT IN CANCER RESEARCH
7.3.3 INCREASING COLLABORATION WITH RESEARCH INSTITUTIONS FOR ANTIBODY DRUG CONJUGATES
7.4 CHALLENGES
7.4.1 CLINICAL TRIAL FAILURES FOR ANTIBODY DRUG CONJUGATES DEVELOPMENT
7.4.2 LENGTHY CLINICAL TRIALS AND DEVELOPMENT PHASES
8 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT
8.1 OVERVIEW
8.2 ENHERTU
8.3 KADCYLA
8.4 TRODELVY
8.5 POLIVY
8.6 ADCETRIS
8.7 PADCEV
8.8 BESPONSA
8.9 ELAHERE
8.1 ZYLONTA
8.11 MYLOTARG
8.12 TIVDAK
8.13 OTHERS
9 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIGEN COMPONENT
9.1 OVERVIEW
9.2 HER2 RECEPTOR
9.3 TROP-2
9.4 CD79B
9.5 CD30
9.6 NECTIN 4
9.7 CD22
9.8 CD19
9.9 CD33
9.1 TISSUE FACTORS
9.11 OTHERS
10 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIBODY COMPONENT
10.1 OVERVIEW
10.2 THIRD GENERATION ADCS
10.3 SECOND GENERATION ADCS
10.4 FOURTH GENERATION ADCS
10.5 FIRST GENERATION ADCS
11 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKERS COMPONENT
11.1 OVERVIEW
11.2 CLEAVABLE LINKERS
11.2.1 PEPTIDE BASED
11.2.2 ACID SENSITIVE OR ACID LABILE
11.2.3 GLUTATHIONE SENSITIVE DISULFIDE
11.3 NON CLEAVABLE LINKERS
12 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT
12.1 OVERVIEW
12.2 DNA DAMAGING AGENTS
12.2.1 CAMPTOTHECIN
12.2.2 CALICHEAMICIN
12.2.3 PYRROLOBENZODIAZEPINES
12.3 MICROTUBULE DISRUPTING AGENTS
12.3.1 AURISTATIN
12.3.2 MAYTANSINOIDS
13 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKER TECHNOLOGY
13.1 OVERVIEW
13.2 PEPTIDE LINKERS
13.3 THIOETHER LINKERS
13.4 HYDRAZONE LINKERS
13.5 DISULFIDE LINKERS
14 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CONJUGATION TECHNOLOGY
14.1 OVERVIEW
14.2 SITE-SPECIFIC CONJUGATION
14.3 CHEMICAL CONJUGATION
15 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY INDICATION
15.1 OVERVIEW
15.2 BREAST CANCER
15.3 BLOOD CANCER (LEUKEMIA, LYMPHOMA)
15.4 LUNG CANCER
15.5 GYNECOLOGICAL CANCER
15.6 GASTROINTESTINAL CANCER
15.7 GENITOURINARY CANCER
15.8 OTHERS
16 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY END USER
16.1 OVERVIEW
16.2 HOSPITALS
16.3 SPECIALTY CENTER
16.4 CLINICS
16.5 AMBULATORY CENTERS
16.6 HOME HEALTHCARE
16.7 OTHERS
17 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL
17.1 OVERVIEW
17.2 DIRECT TENDERS
17.3 RETAIL SALES
17.3.1 HOSPITAL PHARMACY
17.3.2 RETAIL PHARMACY
17.3.3 ONLINE PHARMACY
17.4 OTHERS
18 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION
18.1 NORTH AMERICA
18.1.1 U.S
18.1.2 CANADA
18.1.3 MEXICO
19 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC): COMPANY LANDSCAPE
19.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
20 SWOT ANALYSIS
21 COMPANY PROFILES
21.1 DAIICHI SANKYO, INC.
21.1.1 COMPANY SNAPSHOT
21.1.2 REVENUE ANALYSIS
21.1.3 PRODUCT PORTFOLIO
21.1.4 RECENT DEVELOPMENT
21.2 F. HOFFMANN-LA ROCHE LTD
21.2.1 COMPANY SNAPSHOT
21.2.2 REVENUE ANALYSIS
21.2.3 PRODUCT PORTFOLIO
21.2.4 RECENT DEVELOPMENT
21.3 GILEAD SCIENCES, INC.
21.3.1 COMPANY SNAPSHOT
21.3.2 REVENUE
21.3.3 PRODUCT PORTFOLIO
21.3.4 RECENT DEVELOPMENT
21.4 ASTELLAS PHARMA INC.
21.4.1 COMPANY SNAPSHOT
21.4.2 REVENUE ANALYSIS
21.4.3 PRODUCT PORTFOLIO
21.4.4 RECENT DEVELOPMENT
21.5 TAKEDA PHARMACEUTICAL COMPANY LIMITED
21.5.1 COMPANY SNAPSHOT
21.5.2 REVENUE ANALYSIS
21.5.3 PRODUCT PORTFOLIO
21.5.4 RECENT DEVELOPMENT
21.6 ABBVIE INC.
21.6.1 COMPANY SNAPSHOT
21.6.2 REVENUE
21.6.3 PRODUCT PORTFOLIO
21.6.4 RECENT DEVELOPMENT
21.7 ADC THERAPEUTICS SA
21.7.1 6.1 COMPANY SNAPSHOT
21.7.2 REVENUE ANALYSIS
21.7.3 PRODUCT PORTFOLIO
21.7.4 RECENT DEVELOPMENT
21.8 AMGEN, INC.
21.8.1 COMPANY SNAPSHOT
21.8.2 REVENUE ANALYSIS
21.8.3 PRODUCT PORTFOLIO
21.8.4 RECENT DEVELOPMENT
21.9 ASTRAZENECA
21.9.1 COMPANY SNAPSHOT
21.9.2 REVENUE ANALYSIS
21.9.3 PRODUCT PORTFOLIO
21.9.4 RECENT DEVELOPMENT
21.1 BAYER
21.10.1 COMPANY SNAPSHOT
21.10.2 REVENUE ANALYSIS
21.10.3 PRODUCT PORTFOLIO
21.10.4 RECENT DEVELOPMENT
21.11 BYONDIS
21.11.1 COMPANY SNAPSHOT
21.11.2 PRODUCT PORTFOLIO
21.11.3 RECENT DEVELOPMENT
21.12 EISAI INC
21.12.1 COMPANY SNAPSHOT
21.12.2 REVENUE ANALYSIS
21.12.3 PRODUCT PORTFOLIO
21.12.4 RECENT DEVELOPMENT
21.13 GSK PLC
21.13.1 COMPANY SNAPSHOT
21.13.2 REVENUE ANALYSIS
21.13.3 PRODUCT PORTFOLIO
21.13.4 RECENT DEVELOPMENT
21.14 JOHNSON & JOHNSON SERVICES, INC.
21.14.1 COMPANY SNAPSHOT
21.14.2 REVENUE ANALYSIS
21.14.3 PRODUCT PORTFOLIO
21.14.4 RECENT DEVELOPMENT
21.15 OXFORD BIOTHERAPEUTICS
21.15.1 COMPANY SNAPSHOT
21.15.2 PRODUCT PORTFOLIO
21.15.3 RECENT DEVELOPMENT
21.16 PFIZER INC.
21.16.1 COMPANY SNAPSHOT
21.16.2 REVENUE ANALYSIS
21.16.3 PRODUCT PORTFOLIO
21.16.4 RECENT UPDATES
21.17 REMEGEN
21.17.1 COMPANY SNAPSHOT
21.17.2 PRODUCT PORTFOLIO
21.17.3 RECENT DEVELOPMENTS
21.18 SANOFI
21.18.1 COMPANY SNAPSHOT
21.18.2 REVENUE ANALYSIS
21.18.3 PRODUCT PORTFOLIO
21.18.4 RECENT DEVELOPMENT
21.19 SUTRO BIOPHARMA, INC.
21.19.1 COMPANY SNAPSHOT
21.19.2 REVENUE ANALYSIS
21.19.3 PRODUCT PORTFOLIO
21.19.4 RECENT UPDATES
22 QUESTIONNAIRE
23 RELATED REPORTS
List of Table
TABLE 1 PROJECTED PRICE CHANGE (2024–2030)
TABLE 2 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (USD MILLION)
TABLE 3 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (VOLUME IN UNITS)
TABLE 4 NORTH AMERICA ENHERTU IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 5 NORTH AMERICA KADCYLA IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 6 NORTH AMERICA TRODELVY IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 7 NORTH AMERICA POLIVY IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 8 NORTH AMERICA ADCETRIS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 9 NORTH AMERICA PADCEV IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 10 NORTH AMERICA BESPONSA IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 11 NORTH AMERICA ELAHERE IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 12 NORTH AMERICA ZYLONTA IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 13 NORTH AMERICA MYLOTARG IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 14 NORTH AMERICA TIVDAK IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 15 NORTH AMERICA OTHERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 16 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIGEN COMPONENT, 2022-2031 (USD MILLION)
TABLE 17 NORTH AMERICA HER2 RECEPTOR IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 18 NORTH AMERICA TROP-2 IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 19 NORTH AMERICA CD79B IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 20 NORTH AMERICA CD30 IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 21 NORTH AMERICA NECTIN 4 IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 22 NORTH AMERICA CD22 IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 23 NORTH AMERICA CD19 IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 24 NORTH AMERICA CD33 IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 25 NORTH AMERICA TISSUE FACTORS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 26 NORTH AMERICA OTHERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 27 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIBODY COMPONENT, 2022-2031 (USD MILLION)
TABLE 28 NORTH AMERICA THIRD GENERATION ADCS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 29 NORTH AMERICA SECOND GENERATION ADCS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 30 NORTH AMERICA FOURTH GENERATION ADCS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 31 NORTH AMERICA FIRST GENERATION ADCS IN OPHTHALMOLOGY MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 32 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKERS COMPONENT, 2022-2031 (USD MILLION)
TABLE 33 NORTH AMERICA CLEAVABLE LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 34 NORTH AMERICA CLEAVABLE LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)
TABLE 35 NORTH AMERICA NON CLEAVABLE LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 36 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT, 2022-2031 (USD MILLION)
TABLE 37 NORTH AMERICA DNA DAMAGING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 38 NORTH AMERICA DNA DAMAGING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)
TABLE 39 NORTH AMERICA MICROTUBULE DISRUPTING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 40 NORTH AMERICA MICROTUBULE DISRUPTING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)
TABLE 41 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKER TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 42 NORTH AMERICA PEPTIDE LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 43 NORTH AMERICA THIOETHER LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 44 NORTH AMERICA HYDRAZONE LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 45 NORTH AMERICA DISULFIDE LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 46 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CONJUGATION TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 47 NORTH AMERICA SITE-SPECIFIC CONJUGATION IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 48 NORTH AMERICA CHEMICAL CONJUGATION IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 49 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY INDICATION, 2022-2031 (USD MILLION)
TABLE 50 NORTH AMERICA BREAST CANCER IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 51 NORTH AMERICA BLOOD CANCER (LEUKEMIA, LYMPHOMA) IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 52 NORTH AMERICA LUNG CANCER IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 53 NORTH AMERICA GYNECOLOGICAL CANCER IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 54 NORTH AMERICA GASTROINTESTINAL CANCER IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 55 NORTH AMERICA GENITOURINARY CANCER IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 56 NORTH AMERICA OTHERS IN OPHTHALMOLOGY MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 57 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 58 NORTH AMERICA HOSPITALS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 59 NORTH AMERICA SPECIALTY CENTERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 60 NORTH AMERICA CLINICS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 61 NORTH AMERICA AMBULATORY CENTERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 62 NORTH AMERICA HOME HEALTHCARE IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 63 NORTH AMERICA OTHERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 64 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 65 NORTH AMERICA DIRECT TENDERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 66 NORTH AMERICA RETAIL SALES IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 67 NORTH AMERICA RETAIL SALES IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 68 NORTH AMERICA OTHERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 69 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COUNTRY, 2022-2031 (USD MILLION)
TABLE 70 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (USD MILLION)
TABLE 71 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (VOLUME IN UNITS)
TABLE 72 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (ASP)
TABLE 73 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIGEN COMPONENT, 2022-2031 (USD MILLION)
TABLE 74 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIBODY COMPONENT, 2022-2031 (USD MILLION)
TABLE 75 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKERS COMPONENT, 2022-2031 (USD MILLION)
TABLE 76 NORTH AMERICA CLEAVABLE LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKERS COMPONENT, 2022-2031 (USD MILLION)
TABLE 77 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT, 2022-2031 (USD MILLION)
TABLE 78 NORTH AMERICA DNA DAMAGING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT, 2022-2031 (USD MILLION)
TABLE 79 NORTH AMERICA MICROTUBULE DISRUPTING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT, 2022-2031 (USD MILLION)
TABLE 80 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKER TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 81 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CONJUGATION TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 82 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY INDICATION, 2022-2031 (USD MILLION)
TABLE 83 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 84 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 85 NORTH AMERICA RETAIL SALES IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 86 U.S. ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (USD MILLION)
TABLE 87 U.S. ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (VOLUME IN UNITS)
TABLE 88 U.S. ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (ASP)
TABLE 89 U.S. ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIGEN COMPONENT, 2022-2031 (USD MILLION)
TABLE 90 U.S. ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIBODY COMPONENT, 2022-2031 (USD MILLION)
TABLE 91 U.S. ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKERS COMPONENT, 2022-2031 (USD MILLION)
TABLE 92 U.S. CLEAVABLE LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)
TABLE 93 U.S. ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT, 2022-2031 (USD MILLION)
TABLE 94 U.S. DNA DAMAGING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)
TABLE 95 U.S. MICROTUBULE DISRUPTING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)
TABLE 96 U.S. ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKER TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 97 U.S. ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CONJUGATION TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 98 U.S. ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY INDICATION, 2022-2031 (USD MILLION)
TABLE 99 U.S. ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 100 U.S. ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 101 U.S. RETAIL SALES IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 102 CANADA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (USD MILLION)
TABLE 103 CANADA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (VOLUME IN UNITS)
TABLE 104 CANADA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (ASP)
TABLE 105 CANADA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIGEN COMPONENT, 2022-2031 (USD MILLION)
TABLE 106 CANADA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIBODY COMPONENT, 2022-2031 (USD MILLION)
TABLE 107 CANADA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKERS COMPONENT, 2022-2031 (USD MILLION)
TABLE 108 CANADA CLEAVABLE LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)
TABLE 109 CANADA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT, 2022-2031 (USD MILLION)
TABLE 110 CANADA DNA DAMAGING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)
TABLE 111 CANADA MICROTUBULE DISRUPTING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)
TABLE 112 CANADA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKER TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 113 CANADA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CONJUGATION TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 114 CANADA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY INDICATION, 2022-2031 (USD MILLION)
TABLE 115 CANADA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 116 CANADA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 117 CANADA RETAIL SALES IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 118 MEXICO ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (USD MILLION)
TABLE 119 MEXICO ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (VOLUME IN UNITS)
TABLE 120 MEXICO ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (ASP)
TABLE 121 MEXICO ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIGEN COMPONENT, 2022-2031 (USD MILLION)
TABLE 122 MEXICO ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIBODY COMPONENT, 2022-2031 (USD MILLION)
TABLE 123 MEXICO ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKERS COMPONENT, 2022-2031 (USD MILLION)
TABLE 124 MEXICO CLEAVABLE LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)
TABLE 125 MEXICO ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT, 2022-2031 (USD MILLION)
TABLE 126 MEXICO DNA DAMAGING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)
TABLE 127 MEXICO MICROTUBULE DISRUPTING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)
TABLE 128 MEXICO ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKER TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 129 MEXICO ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CONJUGATION TECHNOLOGY, 2022-2031 (USD MILLION)
TABLE 130 MEXICO ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY INDICATION, 2022-2031 (USD MILLION)
TABLE 131 MEXICO ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 132 MEXICO ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 133 MEXICO RETAIL SALES IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
List of Figure
FIGURE 1 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 8 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: DBMR MARKET POSITION GRID
FIGURE 9 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: SEGMENTATION
FIGURE 11 EXECUTIVE SUMMARY
FIGURE 12 STRATEGIC DECISIONS
FIGURE 13 RISING INCIDENCE OF CANCER IS DRIVING THE GROWTH OF THE NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET FROM 2024 TO 2031
FIGURE 14 THE PRODUCT SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET IN 2024 AND 2031
FIGURE 15 DROC
FIGURE 16 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY PRODUCT, 2023
FIGURE 17 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY PRODUCT, 2024-2031 (USD MILLION)
FIGURE 18 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY PRODUCT, CAGR (2024-2031)
FIGURE 19 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY PRODUCT, LIFELINE CURVE
FIGURE 20 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY ANTIGEN COMPONENT, 2023
FIGURE 21 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY ANTIGEN COMPONENT, 2024-2031 (USD MILLION)
FIGURE 22 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY ANTIGEN COMPONENT, CAGR (2024-2031)
FIGURE 23 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY ANTIGEN COMPONENT, LIFELINE CURVE
FIGURE 24 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY ANTIBODY COMPONENT, 2023
FIGURE 25 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY ANTIBODY COMPONENT, 2024-2031 (USD MILLION)
FIGURE 26 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY ANTIBODY COMPONENT, CAGR (2024-2031)
FIGURE 27 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY ANTIBODY COMPONENT, LIFELINE CURVE
FIGURE 28 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY LINKERS COMPONENT, 2023
FIGURE 29 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY LINKERS COMPONENT, 2024-2031 (USD MILLION)
FIGURE 30 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY LINKERS COMPONENT, CAGR (2024-2031)
FIGURE 31 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY LINKERS COMPONENT, LIFELINE CURVE
FIGURE 32 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT, 2023
FIGURE 33 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT, 2024-2031 (USD MILLION)
FIGURE 34 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT, CAGR (2024-2031)
FIGURE 35 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT, LIFELINE CURVE
FIGURE 36 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY LINKER TECHNOLOGY, 2023
FIGURE 37 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY LINKER TECHNOLOGY, 2024-2031 (USD MILLION)
FIGURE 38 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY LINKER TECHNOLOGY, CAGR (2024-2031)
FIGURE 39 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY LINKER TECHNOLOGY, LIFELINE CURVE
FIGURE 40 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY CONJUGATION TECHNOLOGY, 2023
FIGURE 41 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY CONJUGATION TECHNOLOGY, 2024-2031 (USD MILLION)
FIGURE 42 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY CONJUGATION TECHNOLOGY, CAGR (2024-2031)
FIGURE 43 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY CONJUGATION TECHNOLOGY, LIFELINE CURVE
FIGURE 44 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY INDICATION, 2023
FIGURE 45 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY INDICATION, 2024-2031 (USD MILLION)
FIGURE 46 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY INDICATION, CAGR (2024-2031)
FIGURE 47 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY INDICATION, LIFELINE CURVE
FIGURE 48 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY END USER, 2023
FIGURE 49 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY END USER, 2024-2031 (USD MILLION)
FIGURE 50 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY END USER, CAGR (2024-2031)
FIGURE 51 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY END USER, LIFELINE CURVE
FIGURE 52 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY DISTRIBUTION CHANNEL, 2023
FIGURE 53 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD MILLION)
FIGURE 54 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031)
FIGURE 55 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 56 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET: SNAPSHOT (2023)
FIGURE 57 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC): COMPANY SHARE 2023 (%)
